NOVEL PROTEIN DRUG CONJUGATE FORMULATION
Novel protein drug conjugate formulation The invention provides stable pharmaceutical formulation comprising a protein drug conjugate along with one or more suitable excipient(s) such that the formulation is devoid of any buffer components and methods of making the same. The protein drug conjugate a...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | BANDYOPADHYAY, Sanjay PATEL, Chintan SINGH, Avanish Kumar MENDIRATTA, Sanjeev Kumar |
| description | Novel protein drug conjugate formulation The invention provides stable pharmaceutical formulation comprising a protein drug conjugate along with one or more suitable excipient(s) such that the formulation is devoid of any buffer components and methods of making the same. The protein drug conjugate according to the present invention is antibody drug conjugate, preferably trastuzumab maytansinoid conjugate. Suitable excipient(s) according to the present invention is selected from suitable bulking agents, suitable tonicity modifiers, suitable stabilizers and the like.
L'invention concerne une nouvelle formulation de conjugué protéine-médicament qui produit une formulation pharmaceutique stable comprenant un conjugué protéine-médicament conjointement avec un ou plusieurs excipients appropriés, de telle sorte que la formulation est exempte de composants tampons quelconques, ainsi que des procédés de fabrication de celle-ci. Le conjugué protéine-médicament selon la présente invention est un conjugué anticorps-médicament, de préférence un conjugué de trastuzumab-maytansinoïdes. Un ou plusieurs excipients appropriés selon la présente invention sont choisis parmi des diluants appropriés, des modificateurs de tonicité appropriés, des stabilisants appropriés et analogues. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2018158716A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2018158716A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2018158716A13</originalsourceid><addsrcrecordid>eNrjZNDw8w9z9VEICPIPcfX0U3AJCnVXcPb38wp1dwxxVXDzD_IN9XEM8fT342FgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8eH-RgaGFoamFuaGZo6GxsSpAgC2RiVU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>NOVEL PROTEIN DRUG CONJUGATE FORMULATION</title><source>esp@cenet</source><creator>BANDYOPADHYAY, Sanjay ; PATEL, Chintan ; SINGH, Avanish Kumar ; MENDIRATTA, Sanjeev Kumar</creator><creatorcontrib>BANDYOPADHYAY, Sanjay ; PATEL, Chintan ; SINGH, Avanish Kumar ; MENDIRATTA, Sanjeev Kumar</creatorcontrib><description>Novel protein drug conjugate formulation The invention provides stable pharmaceutical formulation comprising a protein drug conjugate along with one or more suitable excipient(s) such that the formulation is devoid of any buffer components and methods of making the same. The protein drug conjugate according to the present invention is antibody drug conjugate, preferably trastuzumab maytansinoid conjugate. Suitable excipient(s) according to the present invention is selected from suitable bulking agents, suitable tonicity modifiers, suitable stabilizers and the like.
L'invention concerne une nouvelle formulation de conjugué protéine-médicament qui produit une formulation pharmaceutique stable comprenant un conjugué protéine-médicament conjointement avec un ou plusieurs excipients appropriés, de telle sorte que la formulation est exempte de composants tampons quelconques, ainsi que des procédés de fabrication de celle-ci. Le conjugué protéine-médicament selon la présente invention est un conjugué anticorps-médicament, de préférence un conjugué de trastuzumab-maytansinoïdes. Un ou plusieurs excipients appropriés selon la présente invention sont choisis parmi des diluants appropriés, des modificateurs de tonicité appropriés, des stabilisants appropriés et analogues.</description><language>eng ; fre</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2018</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180907&DB=EPODOC&CC=WO&NR=2018158716A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180907&DB=EPODOC&CC=WO&NR=2018158716A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BANDYOPADHYAY, Sanjay</creatorcontrib><creatorcontrib>PATEL, Chintan</creatorcontrib><creatorcontrib>SINGH, Avanish Kumar</creatorcontrib><creatorcontrib>MENDIRATTA, Sanjeev Kumar</creatorcontrib><title>NOVEL PROTEIN DRUG CONJUGATE FORMULATION</title><description>Novel protein drug conjugate formulation The invention provides stable pharmaceutical formulation comprising a protein drug conjugate along with one or more suitable excipient(s) such that the formulation is devoid of any buffer components and methods of making the same. The protein drug conjugate according to the present invention is antibody drug conjugate, preferably trastuzumab maytansinoid conjugate. Suitable excipient(s) according to the present invention is selected from suitable bulking agents, suitable tonicity modifiers, suitable stabilizers and the like.
L'invention concerne une nouvelle formulation de conjugué protéine-médicament qui produit une formulation pharmaceutique stable comprenant un conjugué protéine-médicament conjointement avec un ou plusieurs excipients appropriés, de telle sorte que la formulation est exempte de composants tampons quelconques, ainsi que des procédés de fabrication de celle-ci. Le conjugué protéine-médicament selon la présente invention est un conjugué anticorps-médicament, de préférence un conjugué de trastuzumab-maytansinoïdes. Un ou plusieurs excipients appropriés selon la présente invention sont choisis parmi des diluants appropriés, des modificateurs de tonicité appropriés, des stabilisants appropriés et analogues.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2018</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNDw8w9z9VEICPIPcfX0U3AJCnVXcPb38wp1dwxxVXDzD_IN9XEM8fT342FgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8eH-RgaGFoamFuaGZo6GxsSpAgC2RiVU</recordid><startdate>20180907</startdate><enddate>20180907</enddate><creator>BANDYOPADHYAY, Sanjay</creator><creator>PATEL, Chintan</creator><creator>SINGH, Avanish Kumar</creator><creator>MENDIRATTA, Sanjeev Kumar</creator><scope>EVB</scope></search><sort><creationdate>20180907</creationdate><title>NOVEL PROTEIN DRUG CONJUGATE FORMULATION</title><author>BANDYOPADHYAY, Sanjay ; PATEL, Chintan ; SINGH, Avanish Kumar ; MENDIRATTA, Sanjeev Kumar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2018158716A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2018</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>BANDYOPADHYAY, Sanjay</creatorcontrib><creatorcontrib>PATEL, Chintan</creatorcontrib><creatorcontrib>SINGH, Avanish Kumar</creatorcontrib><creatorcontrib>MENDIRATTA, Sanjeev Kumar</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BANDYOPADHYAY, Sanjay</au><au>PATEL, Chintan</au><au>SINGH, Avanish Kumar</au><au>MENDIRATTA, Sanjeev Kumar</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>NOVEL PROTEIN DRUG CONJUGATE FORMULATION</title><date>2018-09-07</date><risdate>2018</risdate><abstract>Novel protein drug conjugate formulation The invention provides stable pharmaceutical formulation comprising a protein drug conjugate along with one or more suitable excipient(s) such that the formulation is devoid of any buffer components and methods of making the same. The protein drug conjugate according to the present invention is antibody drug conjugate, preferably trastuzumab maytansinoid conjugate. Suitable excipient(s) according to the present invention is selected from suitable bulking agents, suitable tonicity modifiers, suitable stabilizers and the like.
L'invention concerne une nouvelle formulation de conjugué protéine-médicament qui produit une formulation pharmaceutique stable comprenant un conjugué protéine-médicament conjointement avec un ou plusieurs excipients appropriés, de telle sorte que la formulation est exempte de composants tampons quelconques, ainsi que des procédés de fabrication de celle-ci. Le conjugué protéine-médicament selon la présente invention est un conjugué anticorps-médicament, de préférence un conjugué de trastuzumab-maytansinoïdes. Un ou plusieurs excipients appropriés selon la présente invention sont choisis parmi des diluants appropriés, des modificateurs de tonicité appropriés, des stabilisants appropriés et analogues.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2018158716A1 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | NOVEL PROTEIN DRUG CONJUGATE FORMULATION |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T05%3A58%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BANDYOPADHYAY,%20Sanjay&rft.date=2018-09-07&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2018158716A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |